Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PNV001
MIFTS: 50

Panuveitis

Categories: Eye diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Panuveitis

About this section

MalaCards integrated aliases for Panuveitis:

Name: Panuveitis 12 52 58 54 43 15 17 71
Diffuse Uveitis 12 52
Total Uveitis 52 58
Inflammation of the Whole Uveal Tract 52

Characteristics:

Orphanet epidemiological data:

58
panuveitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12030
ICD9CM 34 360.12
MeSH 43 D015864
NCIt 49 C84989
SNOMED-CT 67 75614007
ICD10 32 H44.11
ICD10 via Orphanet 33 H44.1
UMLS via Orphanet 72 C0030343
Orphanet 58 ORPHA280898
UMLS 71 C0030343
Sources

Summaries for Panuveitis

About this section
NIH Rare Diseases : 52 Panuveitis is inflammation of all layers of the uvea of the eye, which includes the iris , ciliary body , and choroid . These make up the middle layer of the eye. The condition can also affect the lens, retina, optic nerve, and vitreous, causing reduced vision or blindness. Signs and symptoms may include eye redness and pain; blurring; light sensitivity; decreased vision; and seeing floaters. It can last for a short time or can occur chronically. Severe cases may recur many times. In many cases the specific cause is unknown, but in some cases it occurs in association with other eye conditions, or with another condition or infection that also affects other body parts. Early treatment is needed and may include eye drops to reduce inflammation and pain; and/or oral medications or injections in severe cases.

MalaCards based summary : Panuveitis, also known as diffuse uveitis, is related to vogt-koyanagi-harada disease and sympathetic ophthalmia. An important gene associated with Panuveitis is UACA (Uveal Autoantigen With Coiled-Coil Domains And Ankyrin Repeats), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Fluocinolone Acetonide and Chlorambucil have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 An uveitis that is characterized by inflammation of all layers of the uvea (middle layer) of the eye, which includes the iris, ciliary body, and choroid.

Sources

Related Diseases for Panuveitis

About this section

Diseases in the Panuveitis family:

Infectious Panuveitis Systemic Diseases with Panuveitis

Diseases related to Panuveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 813)
# Related Disease Score Top Affiliating Genes
1 vogt-koyanagi-harada disease 33.1 IL17A IL10 IFNA2 HLA-DRB1 HLA-DQB1
2 sympathetic ophthalmia 33.0 TNF RBP3 IL10 HLA-DRB1
3 multifocal choroiditis 31.8 TNF IL10
4 macular retinal edema 31.3 TNF MRAP ACE
5 pars planitis 31.3 RBP3 MRAP HLA-DRB1 CCR6
6 uveitis 31.3 TNFRSF1B TNF SAG RBP3 IL17A IL10
7 punctate inner choroidopathy 31.2 TNF IL10
8 intermediate uveitis 31.1 TNF MRAP IL10 HLA-DRB1 CCR6
9 neurosyphilis 31.0 IL17A IL10
10 posterior uveitis 30.9 TNF SAG RBP3 MRAP ICOSLG CCR6
11 optic neuritis 30.9 TNF IL10 HLA-DRB1
12 toxoplasmosis 30.8 TNF IL10 HLA-DQB1 CD40LG
13 ocular toxoplasmosis 30.7 IL17A CD40LG
14 relapsing polychondritis 30.7 IL17A IL10 CRP
15 endophthalmitis 30.7 TNF SAG MRAP CRP CD4
16 leptospirosis 30.6 TNF IL10 CRP CD40LG
17 scleritis 30.5 TNFRSF1B TNF MRAP CRP CCR6
18 cutaneous leishmaniasis 30.5 TNF IL17A IL10
19 dengue disease 30.5 TNF ICOSLG CD40LG
20 retinal vascular disease 30.5 TNF CRP ACE
21 keratitis, hereditary 30.5 TNF IL17A CD4 CCR6
22 asymptomatic neurosyphilis 30.5 CD40LG CD4
23 peritonitis 30.4 TNF IL17A IL10 CRP
24 dermatitis 30.4 TNF IL17A IL10 CCR6
25 granuloma annulare 30.4 TNFRSF1B TNF CD4
26 graft-versus-host disease 30.4 TNF IL10 HLA-DRB1 HLA-DQB1
27 meningitis 30.3 TNF IL17A IL10 CRP CD40LG
28 aseptic meningitis 30.3 TNF IL10 CRP CD40LG
29 pulmonary tuberculosis 30.3 TNF IL10 HLA-DRB1 HLA-DQB1 CRP
30 cytomegalovirus retinitis 30.3 TNF IL10 HLA-DRB1 HLA-DQB1 CD40LG CD4
31 neuroretinitis 30.3 SAG MRAP CRP CD40LG CD4 ACE
32 ocular tuberculosis 30.3 MRAP CD4 ACE
33 juvenile rheumatoid arthritis 30.3 TNFRSF1B TNF IL10 HLA-DRB1 HLA-DQB1 CRP
34 birdshot chorioretinopathy 30.2 RBP3 MRAP IL17A ERAP1 CCR6
35 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 30.2 TNF IL10 CD4
36 aspergillosis 30.2 TNFRSF1B TNF IL10 CCR6
37 familial mediterranean fever 30.2 TNF IL17A IL10 CRP
38 proteasome-associated autoinflammatory syndrome 1 30.2 TNF IL17A IL10 CRP
39 visceral leishmaniasis 30.2 TNF IL10 HLA-DRB1 CRP
40 hypopyon 30.2 TNFRSF1B TNF RBP3 MRAP IL17A IL10
41 filariasis 30.2 TNFRSF1B TNF IL10 CRP
42 histiocytosis 30.2 TNF SERPINA3 IL17A CCR6
43 multiple cranial nerve palsy 30.1 CRP ACE
44 cheilitis 30.1 TNF ERAP1 CD4 CCR6
45 yellow fever 30.1 IL17A CRP CCR6
46 vasculitis 30.1 TNFRSF1B TNF SERPINA3 IL17A IL10 IFNA2
47 autoimmune uveitis 30.1 TNF SAG RBP3 IL17A IL10
48 toxocariasis 30.1 MRAP IL10 CRP CD40LG
49 histoplasmosis 30.1 TNFRSF1B TNF IL17A HLA-DRB1 CD40LG CD4
50 cat-scratch disease 30.1 CRP CD40LG CD4 ACE

Graphical network of the top 20 diseases related to Panuveitis:



Diseases related to Panuveitis
Sources

Symptoms & Phenotypes for Panuveitis

About this section

GenomeRNAi Phenotypes related to Panuveitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 CD40LG IL10 IL17A TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 ACE HLA-DQB1 IL10 IL17A TNF TNFRSF1B

MGI Mouse Phenotypes related to Panuveitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10 ACE CD4 CD40LG ERAP1 HLA-DQB1 IL10
2 hematopoietic system MP:0005397 9.9 ACE CCR6 CD4 CD40LG ERAP1 HLA-DQB1
3 homeostasis/metabolism MP:0005376 9.8 ACE CCR6 CD4 CD40LG CRP HLA-DQB1
4 immune system MP:0005387 9.4 ACE CCR6 CD4 CD40LG CRP ERAP1
Sources

Drugs & Therapeutics for Panuveitis

About this section

Drugs for Panuveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
2
Chlorambucil Approved Phase 4 305-03-3 2708
3
Mycophenolic acid Approved Phase 4 24280-93-1 446541
4
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
5
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
6
Azathioprine Approved Phase 4 446-86-6 2265
7
Infliximab Approved Phase 4 170277-31-3
8 Cyclosporins Phase 4
9 Calcineurin Inhibitors Phase 4
10 Gastrointestinal Agents Phase 4
11 Antitubercular Agents Phase 4
12 Alkylating Agents Phase 4
13 Hormone Antagonists Phase 4
14 Hormones Phase 4
15 Adrenocorticotropic Hormone Phase 4
16 Melanocyte-Stimulating Hormones Phase 4
17 beta-Endorphin Phase 4
18
Adalimumab Approved Phase 3 331731-18-1 16219006
19
Difluprednate Approved Phase 3 23674-86-4 443936
20
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
21
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
22
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
23
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
24 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
25
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
26
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
27
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
28 Triamcinolone diacetate Phase 3
29 triamcinolone acetonide Phase 3
30 Triamcinolone hexacetonide Phase 3
31 Interferon alpha-2 Phase 3
32 Methylprednisolone Acetate Phase 3
33 interferons Phase 3
34 Interferon-alpha Phase 3
35 Anti-Infective Agents Phase 3
36 Antiviral Agents Phase 3
37 Anti-Bacterial Agents Phase 3
38 Antibiotics, Antitubercular Phase 3
39 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
40 Immunoglobulins Phase 3
41 Antibodies Phase 3
42 Antibodies, Monoclonal Phase 3
43 Pharmaceutical Solutions Phase 3
44
tannic acid Approved Phase 2 1401-55-4
45
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
46
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
47
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
48
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
49
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
50
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
2 A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of Acthar Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU) Suspended NCT03656692 Phase 4 Acthar Gel
3 A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye Unknown status NCT02746991 Phase 3 Sham Injection;FAI Insert
4 A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
5 Phase 3 Open-Labeled Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Severe Anterior Uveitis (Including Panuveitis). Completed NCT00407056 Phase 3 Difluprednate Ophthalmic Emulsion
6 Phase 3 Confirmatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Including Panuveitis). Completed NCT00406887 Phase 3 Difluprednate Ophthalmic Emulsion
7 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
8 Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis Completed NCT03097315 Phase 3
9 Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
10 A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis Completed NCT00404885 Phase 3 Placebo;LX211;LX211;LX211
11 A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
12 A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
13 A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
14 A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT01148225 Phase 3 adalimumab
15 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01138657 Phase 3 Prednisone;Placebo
16 First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial Completed NCT01829295 Phase 3 Mycophenolate mofetil;Methotrexate;Prednisone
17 A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
18 A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis. Terminated NCT01032915 Phase 3 Placebo
19 A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01103024 Phase 3
20 A 38-week Extension to a 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet's Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy (SHIELD Study) Terminated NCT01093846 Phase 3 AIN457;AIN457;Placebo AIN457
21 A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
22 An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects With Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Patients Who Each Successfully Completed Either the X052130/CL3-78989-005 (EYEGUARDâ„¢-A) or the X052131/CL3-78989-006 (EYEGUARDâ„¢-C) Study or Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133 (EYEGUARDâ„¢-US) Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
23 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment Terminated NCT01747538 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
24 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis Terminated NCT01684345 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
25 A Multicenter, Open-label Study to Evaluate the Long Term Clinical Use of Treatment With AIN457 in Patients Completing Clinical Trials Investigating AIN457 for the Treatment of Non-infectious Intermediate, Posterior or Panuveitis Withdrawn NCT01327664 Phase 3
26 Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Unknown status NCT01717170 Phase 1, Phase 2 Tocilizumab
27 A Multicenter, Single Sequence, Open-label Study to Assess the Tolerability, Safety, and Efficacy of 2 Weeks Oral AEB071 300 mg Twice Daily, Followed by 6 Weeks AEB071 200 mg Twice Daily in the Treatment of Patients With Macular Edema Associated With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT00615693 Phase 2 AEB071
28 An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis Completed NCT00685399 Phase 2 AIN457;AIN 457;AIN457
29 Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
30 Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Inluding Iritis, Cyclitis, Iridocyclitis, and Panuveitis). Completed NCT00405496 Phase 2 Difluprednate Ophthalmic Emulsion
31 A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, Posterior-, or Panuveitis Requiring Systemic Immunosuppressive Therapy Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
32 A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
33 Pilot Study of Leflunomide for the Treatment of Uveitis Completed NCT00001863 Phase 2 Leflunomide
34 A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis Recruiting NCT03308045 Phase 1, Phase 2
35 A Pilot Study to Investigate Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis Recruiting NCT02911116 Phase 2 Ustekinumab;Ustekinumab
36 Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis Recruiting NCT01280669 Phase 2 Intravitreal injection 440mcg;Intravitreal injection of sirolimus 880mcg
37 A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU) Recruiting NCT03847272 Phase 2 prednisone and ustekinumab treatment
38 A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease Active, not recruiting NCT02648581 Phase 2 Subcutaneous Ustekinumab
39 Treatment of Non-infectious Panuveitis, Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate Terminated NCT01314417 Phase 1, Phase 2 Methotrexate
40 A Multicenter, Randomized, Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of FTY720 in Patients With Acute, Noninfectious Intermediate, Posterior and Pan Uveitis Withdrawn NCT01791192 Phase 2 FTY720;Oral Corticosteroid
41 A Pilot Study to Investigate Ustekinumab (StelaraTM) for the Treatment of Active Sight-Threatening Uveitis Withdrawn NCT01647152 Phase 1, Phase 2 Ustekinumab
42 A Phase I/IIa Study of the Treatment of None-Infectious Anterior, Intermediate, Posterior and Panuveitis, With the Use of Dexamethasone Delivered by a Iontophoresis Device Withdrawn NCT00499551 Phase 1, Phase 2
43 Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis Completed NCT01781936 Phase 1 Fluocinolone Acetonide
44 A Phase 1, Open-label, Randomized Clinical Study to Assess the Safety, Tolerability and Bioactivity of Intravitreal and Subconjunctival Injection of Sirolimus in Patients With Non-infectious Uveitis Completed NCT00908466 Phase 1 Sirolimus (rapamycin);Sirolimus (rapamycin)
45 The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma Completed NCT00943982 Phase 1 Interferon Gamma 1-b
46 Quality of Life and Visual Function in Uveitis Patients Unknown status NCT00407316
47 Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice -HOPE Completed NCT03155243
48 Multi-Center, Non-Interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated With Non-Infectious Uveitis Completed NCT02952001 4mg CLS-TA Suprachoriodal Injection
49 Combined Fluocinolone Acetonide Sustained Drug Delivery System Implantation and Phacoemulsification/Intraocular Lens Implantation in Patients With Severe Uveitis Completed NCT00570830
50 Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis Completed NCT00609687

Search NIH Clinical Center for Panuveitis

Cochrane evidence based reviews: panuveitis

Sources

Genetic Tests for Panuveitis

About this section
Sources

Anatomical Context for Panuveitis

About this section

MalaCards organs/tissues related to Panuveitis:

40
Eye, Retina, T Cells, Testes, Endothelial, Bone Marrow, Bone
Sources

Publications for Panuveitis

About this section

Articles related to Panuveitis:

(show top 50) (show all 1420)
# Title Authors PMID Year
1
Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study. 54 61
9713053 1998
2
Seronegative ocular toxoplasma panuveitis in an immunocompetent patient. 61
32566798 2020
3
Approach to Cataract Surgery in an Ebola Virus Disease Survivor with Prior Ocular Viral Persistence. 61
32568043 2020
4
Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis. 61
32408154 2020
5
Yellow Sub-Retinal Pigment Epithelium (YSRPE) Deposits: A Novel Sign in Ocular Tuberculosis. 61
32541431 2020
6
Transient mydriasis in toxoplasmosis retinochoroiditis. 61
32346651 2020
7
Rhegmatogenous retinal detachment masquerading as exudative panuveitis with intense anterior chamber inflammatory reaction. 61
32154433 2020
8
Bilateral acute retinal necrosis caused by two separate viral etiologies. 61
32154437 2020
9
Clinical utility of aqueous humor polymerase chain reaction and serologic testing for suspected infectious uveitis: a single-center retrospective study in South Korea. 61
32560636 2020
10
Survey among retina specialists in Brazil about inflammatory reactions after intravitreal antiangiogenic therapy. 61
32049159 2020
11
Autologous Descemet Stripping Automated Endothelial Keratoplasty to Eliminate Endothelial Rejection in Eyes at High Risk. 61
31688200 2020
12
A Case Report of Sweet's Syndrome with Panuveitis and Rhegmatogenous Retinal Detachment. 61
32394773 2020
13
Pediatric Uveitis in a Referral Center in North Part of Turkey. 61
32463707 2020
14
Altered gut microbiome composition in patients with Vogt-Koyanagi-Harada disease. 61
31928124 2020
15
Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics. 61
32168001 2020
16
[Ocular Syphilis - Update]. 61
32434244 2020
17
Vogt-Koyanagi-Harada disease: recurrence rates after initial-onset disease differ according to treatment modality and geographic area. 61
32418076 2020
18
[Uveitis in Behçet's Syndrome in Germany - Prognosis During Current Therapy]. 61
32434242 2020
19
Moth hair in cornea in a case of seasonal hyperacute panuveitis. 61
32317495 2020
20
Rifabutin-associated acute bilateral panuveitis mimicking endophthalmitis in an immunocompetent patient. 61
32065716 2020
21
Intraocular leucocyte subpopulations analysis by multiparametric flow cytometry in human uveitis. 61
32424059 2020
22
Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant. 61
32114654 2020
23
Outcome and risk of ocular complications of managing children with chronic anterior uveitis with topical rimexolone 1. 61
32318939 2020
24
Efficacy of Adalimumab in Non-Infectious Uveitis Across Different Etiologies: A Post Hoc Analysis of the VISUAL I and VISUAL II Trials. 61
32469621 2020
25
Toxoplasma gondii SAG2 type III in an atypical presentation of ocular toxoplasmosis in Indonesia. 61
32413604 2020
26
A Clinical Audit on the Predictors for Visual Morbidity in Patients with Behçet's Disease Attending Cairo University Hospitals. 61
32475197 2020
27
Epidemiology of 2000 Chinese uveitis patients from Northeast China. 61
32424058 2020
28
Local therapy for cancer therapy-associated uveitis: a case series and review of the literature. 61
31409649 2020
29
[Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis]. 61
31818505 2020
30
The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings. 61
32250731 2020
31
Resurgence of ocular syphilis in British Columbia between 2013-2016: a retrospective chart review. 61
31889521 2020
32
BILATERAL SEROUS RETINAL DETACHMENT AND UVEITIS ASSOCIATED WITH PEMBROLIZUMAB TREATMENT IN METASTATIC MELANOMA. 61
32243282 2020
33
Blau syndrome following a bacterial infection. 61
32045678 2020
34
Development of Acute Vogt-Koyanagi-Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma. 61
31161956 2020
35
Poor Control of Sarcoidosis-Related Panuveitis with an Antibody to IL-23. 61
30811269 2020
36
Clinical Profile in Genetically Proven Blau Syndrome: A Case Series from South India. 61
32293936 2020
37
Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG. 61
32018067 2020
38
Pattern and Outcome of Uveitis in a Tertiary Military Hospital in Thailand. 61
31009267 2020
39
Localized Peripheral Vitritis on OCT in Multifocal Choroiditis and Panuveitis. 61
32273110 2020
40
Pathogenesis of Uveitis in Ebola Virus Disease Survivors: Evolving Understanding from Outbreaks to Animal Models. 61
32325950 2020
41
Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program. 61
32564920 2020
42
Disease of the Year 2019: Ocular Toxoplasmosis in HIV-infected Patients. 61
32162993 2020
43
Clinical Features and Visual Outcome of Uveitis in Japanese Patients Younger than 18 Years. 61
32162972 2020
44
Prevalence and clinical features of systemic diseases in Chinese patients with uveitis. 61
32188681 2020
45
Clinical and laboratory characteristics of ocular syphilis and neurosyphilis among individuals with and without HIV infection. 61
32220852 2020
46
Diagnostic dilemma: Unilateral panuveitis mimicking endophthalmitis in very severe HLA B27-associated uveitis. 61
31970307 2020
47
Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. 61
31607412 2020
48
Can the CRP/albumin Ratio be Used as a New Indicator of Activation in Patients with Uveitis? 61
32125910 2020
49
Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis. 61
32199631 2020
50
[Clinical features of patients with Behcet's uveitis]. 61
32187951 2020
Sources

Variations for Panuveitis

About this section
Sources

Expression for Panuveitis

About this section
Search GEO for disease gene expression data for Panuveitis.
Sources

Pathways for Panuveitis

About this section

Pathways related to Panuveitis according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.76 TNFRSF1B TNF SERPINA3 IL17A IL10 IFNA2
2
PAK Pathway 63
Show member pathways
 13.24 TNFRSF1B TNF IL17A IL10 CD40LG CD4
3
Cytokine Signaling in Immune system 65
Show member pathways
 13.17 TNFRSF1B TNF IL17A IL10 IFNA2 HLA-DRB1
4
T cell receptor signaling pathway 36
Show member pathways
 12.54 TNF IL17A IL10 CD40LG CD4
5
NF-kappaB Signaling 4
12.51 TNFRSF1B TNF IL17A IL10 CD40LG
6
Th17 cell differentiation 36
Show member pathways
 12.45 TNF IL17A IL10 HLA-DRB1 HLA-DQB1 CD4
7
ICos-ICosL Pathway in T-Helper Cell 63
Show member pathways
 12.3 ICOSLG HLA-DRB1 HLA-DQB1 CD40LG CD4
8
Human T-cell leukemia virus 1 infection 36
12.28 TNF HLA-DRB1 HLA-DQB1 CD4
9
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.27 TNFRSF1B TNF IL10 CCR6
10
CD28 co-stimulation 65
Show member pathways
 12.16 ICOSLG HLA-DRB1 HLA-DQB1 CD4
11
Toxoplasmosis 36
Show member pathways
 12.15 TNF IL10 HLA-DRB1 HLA-DQB1 CD40LG
12
Immune response NFAT in immune response 22
Show member pathways
 12.12 TNFRSF1B TNF IL10 ICOSLG HLA-DRB1 HLA-DQB1
13
Tuberculosis 36
12.11 TNF IL10 IFNA2 HLA-DRB1 HLA-DQB1
14
Allograft rejection 1 36
Show member pathways
 12.02 TNF IL17A IL10 IFNA2 ICOSLG HLA-DRB1
15
Cell adhesion molecules (CAMs) 36
11.94 ICOSLG HLA-DRB1 HLA-DQB1 CD40LG CD4
16
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.93 TNF IL10 IFNA2 CD4
17
Interleukin-4 and 13 signaling 65
11.92 TNFRSF1B TNF IL17A IL10
18
IL27-mediated signaling events 1
Show member pathways
 11.87 TNF IL17A IL10 CD4
19
Visual Cycle in Retinal Rods 63
11.85 SERPINA3 SAG RBP3 CRP
20
Hematopoietic cell lineage 36
11.83 TNF HLA-DRB1 HLA-DQB1 CD4
21
Rheumatoid arthritis 36
11.78 TNF IL17A HLA-DRB1 HLA-DQB1
22
TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions 64
Show member pathways
 11.74 TNFRSF1B TNF CD40LG
23
G-protein signaling N-RAS regulation pathway 22
Show member pathways
 11.72 HLA-DRB1 HLA-DQB1 CD4
24
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 22
Show member pathways
 11.69 TNFRSF1B TNF CD40LG
25
CTLA4 Signaling 63
11.67 HLA-DRB1 HLA-DQB1 CD4
26
Dendritic Cells Developmental Lineage Pathway 64
11.66 TNF IL10 IFNA2 CD4
27
Malaria 36
11.49 TNF IL10 CD40LG
28
Interleukin-10 signaling 65
11.48 TNFRSF1B TNF IL10
29
Innate Lymphoid Cells Differentiation 64
11.46 TNF IL17A IL10 CD4 CCR6
30
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 64
Show member pathways
 11.32 TNFRSF1B TNF IL10
31
Cytokines and Inflammatory Response 1
11.02 TNF IL10 HLA-DRB1 CD4
Sources

GO Terms for Panuveitis

About this section

Cellular components related to Panuveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.9 TNF SERPINA3 RBP3 IL17A IL10 IFNA2
2 extracellular region GO:0005576 9.77 UACA TNFRSF1B TNF SERPINA3 RBP3 IL17A
3 external side of plasma membrane GO:0009897 9.23 TNF IL17A ICOSLG HLA-DRB1 CD40LG CD4

Biological processes related to Panuveitis according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.93 IFNA2 ICOSLG HLA-DRB1 ERAP1 CD4
2 T cell receptor signaling pathway GO:0050852 9.76 ICOSLG HLA-DRB1 HLA-DQB1 CD4
3 B cell differentiation GO:0030183 9.75 IL10 IFNA2 CD40LG
4 humoral immune response GO:0006959 9.69 TNF IFNA2 CCR6
5 cytokine-mediated signaling pathway GO:0019221 9.63 TNFRSF1B TNF IL17A IL10 IFNA2 CD4
6 positive regulation of monocyte differentiation GO:0045657 9.58 HLA-DRB1 CD4
7 positive regulation of viral entry into host cell GO:0046598 9.57 HLA-DRB1 CD4
8 negative regulation of lipid storage GO:0010888 9.56 TNF CRP
9 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.55 TNF IL17A
10 endothelial cell apoptotic process GO:0072577 9.52 TNF IL10
11 B cell proliferation GO:0042100 9.5 IL10 IFNA2 CD40LG
12 inflammatory response GO:0006954 9.5 TNFRSF1B TNF SERPINA3 IL17A IFNA2 CRP
13 negative regulation of cytokine production involved in immune response GO:0002719 9.49 TNF IL10
14 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.48 HLA-DRB1 HLA-DQB1
15 regulation of immunoglobulin secretion GO:0051023 9.43 TNF CD40LG
16 negative regulation of cytokine secretion involved in immune response GO:0002740 9.4 TNF IL10
17 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.37 HLA-DRB1 HLA-DQB1
18 immune response GO:0006955 9.28 TNFRSF1B TNF IL17A IL10 HLA-DRB1 HLA-DQB1
19 receptor biosynthetic process GO:0032800 9.26 TNF IL10

Molecular functions related to Panuveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 TNF IL17A IL10 IFNA2 CD40LG
2 MHC class II receptor activity GO:0032395 8.96 HLA-DRB1 HLA-DQB1
Sources

Sources for Panuveitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....